Anoro Ellipta Approved for COPD
WEDNESDAY, Dec. 18, 2013 (HealthDay News) -- Anoro Ellipta (umeclidinium and vilanterol inhalation powder) has been approved by the U.S. Food and Drug Administration for once-daily treatment of chronic obstructive pulmonary disease (COPD).
COPD, an umbrella term that includes the lung diseases bronchitis and emphysema, is a progressive condition that interferes with breathing. Symptoms may include chest tightness, chronic cough and overproduction of phlegm. It's the third-leading cause of death in the United States, the FDA said in a news release.
Anoro Ellipta, a combination of two approved medications, relaxes the lung airways to help breathing. The drug's safety and effectiveness were evaluated in clinical trials involving more than 2,400 people diagnosed with COPD.
The drug's label includes a warning that users have an increased risk of asthma-related death. However, the medication has not been evaluated in people with asthma, nor should it be taken as a treatment for asthma or for sudden breathing problems, the agency stressed.
Potential serious side effects of the new drug include narrowing of the respiratory airways, cardiovascular problems, glaucoma and worsening urinary retention. The most common side effects include sore throat, sinus infection, respiratory tract infection, constipation, diarrhea, extremity pain and muscle spasms.
Anoro Ellipta is produced by GlaxoSmithKline, based in Research Triangle Park, N.C.
More information
The U.S. National Library of Medicine has more about COPD.
Related Articles
Search Allergy Articles
Black, Hispanic Patients With Severe Allergies Less Likely to Get Allergy Shots
Stay Independent of Allergies, Asthma This July Fourth
Is It Allergies or Sinusitis? Many Folks Are Misdiagnosed
Asthma, Lower Grades, Homelessness: How Climate Change Will Harm America's Kids
Vaping Raises a Teen's Odds of Developing Asthma
Resolve to Keep Your Allergies, Asthma in Check in 2024
Asthma Inhaler Switch in 2024 Could Leave Some Patients Scrambling
Wildfire Smoke Is Reversing Recent Clean-Air Gains Across the U.S.